EVIDENCE GENERATION

FOCUS AREA WORKING GROUP

The mission of the Evidence Generation Focus Area Working Group (FAWG) is to educate the MAPS membership on contemporary practices for data generation strategies, including the design, implementation, and communication of new evidence, and educate the MAPs membership how real-world (RW) evidence may be utilized to support product value; including labeling changes.

Activities: 

To reach our goals, the Evidence Generation FAWG will execute on two key objectives. First, through educational programs and communications, we will increase understanding of requirements for Evidence Generation in the context of Medical Affairs strategic planning & execution of evidence generation plans. Second, we will explore applications of real-world evidence across stakeholders within Medical Affairs, with the purpose of increasing the acceptance of real-world evidence for regulatory purposes.

As part of this plan, we will organize a host of Evidence Generation activities including workshops for MAPS meetings in the North America, with longer term plans and aspirations of conducting Evidence Generation workshops in APAC (Asia Pacific – China/Japan), and EMEA (Europe, Middle East, Asia) regions.

We will develop original content for webinars, podcasts, eLearning courses, and white papers. In addition, the working group will periodically contribute cogent and timely content on the Evidence Generation sector for the MAPS publication, Elevate magazine. Most importantly, we will provide a supportive resource for all Medical Affairs professionals seeking advice and direction on data generation and regulatory strategies.

Strategic Objectives

  1. Enhance foundational knowledge, standards and technical skills for evidence generation:
    • Develop understanding of standards and guidance for evidence generation.
    • Support planning & execution of evidence generation strategy in Medical Affairs.
  2. Increase opportunities for evidence generation:
    • Explore applications of real-world evidence across Regions.
    • Increase transparency and acceptance of real-world evidence.

LATEST PODCAST EPISODE

Description: MAPS speaks with Kent Summers, HEOR Lead at AlphaGroup and Steve Camper, VP of Medical Affairs at Blue Earth Diagnostics, about building Health Economics and Outcomes Research capabilities within Medical Affairs.

FAWG OVERVIEW

MEMBERS

RESOURCES RELATED TO EVIDENCE GENERATION

Shifting the Paradigm (and Price) on Integrated Evidence Generation

Shifting the Paradigm (and Price) on Integrated Evidence Generation

In this on-demand webinar, learn how to shift the paradigm on integrated evidence generation.
Collaborative Content Featured

Collaborative Scientific Content Development: Meeting the Needs of MSLs and KOLs

This article highlights a collaborative approach to content creation in which insights from MSLs were used to develop concepts for educational tools that were shared with key opinion leaders (KOLs).
Evidence Generation Standards Guidance Featured

Evidence Generation Standards and Guidance

This Standard and Guidance is intended to inform learners about the Evidence Generation function, strategic direction, and operations across multiple geographies.
EC RWE Patient Outcomes

Executive Vision: The Role of Medical Affairs in Improving Patient Outcomes with Real-World Evidence

The growth of Real-World Evidence (RWE) from sources including patient registries, claims data, electronic medical records, digital health technologies and more has powered the ability of Medical Affairs to drive patient outcomes. Here, the MAPS Executive Consortium describes how.

Transforming Evidence Generation with Data Visualization: New Approaches for Medical Affairs

As evidence generation becomes more advanced and integrated into Medical Affairs strategic plans, there is a greater need to maximize its impact by leveraging emerging digital technologies to communicate complex clinical and nonclinical data.
Real-World Evidence: What Can You Say to Payers and Patient Advocates?

Real-World Evidence: What Can You Say to Payers and Patient Advocates?

This presentation, part 3 of 3, provides insights into the types of communications that the FDA has indicated are or are not permissible, and the uncertainties that still remain.
Lost your password? Please enter your username or email address. You will receive a link to create a new password via email.